Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Gertner J
Authors: Gertner J, McSweeney A, Furtado O'Mahony L, Quaglia E, John A,
Keywords: homecare,
Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cella D
Authors: Feuilly M, Jenni E, Cella D,
Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,
Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hautefeuille V
Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,
Keywords: Patients’ perception of information, Quality of Life, Lanreotide,
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,
Keywords: Neuroendocrine tumours, lanreotide,
Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,
Keywords: somatostatin analogues, treatment patterns, resource use,